Major public health concerns associated with the diagnosis of prostate cancer are over-diagnosis and over-treatment. The current diagnosis of prostate cancer involves a transrectal ultrasound (TRUS) guided biopsy of the prostate gland to rule out any malignancy (presence of a malignant tumor). The need for a TRUS biopsy is determined by a suspicious digital rectal examination and an increased serum prostate specific antigen (PSA) which is the most widely used biomarker. However, this current method lacks specificity and sensitivity where a raised level of PSA could be brought about by other non-malignant medical conditions. This unfortunately, leads to erroneous and unnecessary diagnostic intervention and radical clinical therapies. This technology aims to provide a platform for a more accurate diagnosis and discrimination of prostate cancer from non-cancer conditions via the use of specific peptide biomarkers.
This innovation aims to provide a platform for a more accurate diagnosis and discrimination of prostate cancer from non-cancer conditions via the use of specific peptide biomarkers.This invention has numerous strengths that capitalises on weaknesses that exist with currently used methods of diagnosis. The efficacy of this method in using ratios of the biomarkers to discriminate between healthy people, patients with benign prostatic hyperplasia and prostate cancer renders it as a suitable, more reliable alternative to conventional diagnosis methods.This diagnosis method for prostate cancers is highly beneficial in providing a more accurate means for diagnosis and discrimination of prostate cancers. The efficiency of this method and its high specificity reduces instances of the diagnosis of low grade and insignificant cancers. This invention as a whole provides the means necessary for reducing or even overcoming the persisting problem of over-diagnosis and over-treatment in the management of prostate cancers.
These unique biomarkers allow high specificity and sensitivity. Comparison of ratios with healthy patients, patients with prostate cancer and those with benign condition provide for higher specificity. This can also discriminate prostate cancer from similar medical condition known as benign prostatic hyperplasia (BPH). Accurate discrimination of prostate cancer is often hindered by BPH. The specificity of this invention, compared to conventional methods, gives it the edge over all other diagnosis methods and minimises the diagnosis of low grade and insignificant cancers.